Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes

NCT01632904 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT01632904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01632904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2012
Completion date
May 31, 2016
Enrollment
110 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

polycythemia vera